Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Addition Therapeuticsadditiontx.comAddition Therapeutics is developing PRINT™ technology, which combines the safety and scalability of RNA therapeutics with the multi-year durability of gene therapies. The company is initially focused on rare, life-threatening diseases with severe unmet needs, aiming to deliver functional cures through its pipeline of PRINTed genetic medicines.
Parse Score
Sources
biopharmadive.com shapes more of what AI says about Addition Therapeutics than any other source, at 100% of its citations.
